Abstract:Background: RET fusion has reported in 1–2% of lung adenocarcinomas, and it is one of the key driver mutations and an actionable target. Non-small cell lung cancer (NSCLC) patients harboring RET fusion can obtained clinical benefit from the therapy with multi-kinase inhibitors like cabozantinib and potent and highly selective RET inhibitors like selpercatinib (LOXO-292) and pralsetinib (BLU-667). In NSCLC, several partners of RET have been reported. However, to the best of our knowledge, no report is available… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.